We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05129189
Recruitment Status : Recruiting
First Posted : November 22, 2021
Last Update Posted : September 19, 2022
Sponsor:
Information provided by (Responsible Party):
Jun Chen, MD, Shanghai Public Health Clinical Center

Brief Summary:
In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block PD-1/PD-L1 signaling may promote the secretion of antiviral cytokines and achieve HIV clearance.The mechanism of action of ASC22 is to competitively block the binding of PD-1 molecules to PD-L1 through its antigen-binding region with a high affinity for hPD-L1, thereby stimulating an innate or adaptive immune response with sustained T-cell activation.This study was conducted to evaluate whether ASC22 combined with chidamide in HIV-infected patients with antiviral suppression could shrink the viral reservoir.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: ASC22 group Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide
Actual Study Start Date : June 29, 2022
Estimated Primary Completion Date : July 30, 2023
Estimated Study Completion Date : July 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: ASC22 group
ASC22 1mg/kg hypodermic injection Q4W+Chidamide 10mg PO BIW
Drug: ASC22 group
The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.




Primary Outcome Measures :
  1. HIV-1 DNA levels [ Time Frame: 52 weeks ]
    Change in HIV-1 DNA levels from baseline at each cycle of treatment


Secondary Outcome Measures :
  1. CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio [ Time Frame: 52 weeks ]
    Changes in CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio, and change from baseline at each cycle of treatment

  2. HIV gag-specific CD8+ T ratio [ Time Frame: 52 weeks ]
    Change from baseline in HIV gag-specific CD8+ T ratio at each cycle of treatment

  3. HIV-1 RNA [ Time Frame: 52 weeks ]
    Change in HIV-1 RNA from baseline at each cycle of treatment


Other Outcome Measures:
  1. Treatment-Emergent Adverse Events [ Time Frame: 52 weeks ]
    All adverse events occurred after drug administration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. People diagnosed with HIV infection.
  2. Age ≥18 years.
  3. In good general health with a body mass index ≥18.0 to <35.0 kg/m2.
  4. Able to comply with the time requirements for study visits and assessments.
  5. Currently on cART for at least 24 months with two consecutive plasma HIV-1 RNA < 50 copies/ml at least 12 months apart.
  6. CD4+ T-cell count ≥ 250 cells/µl (including borderline values) and CD4/CD8 < 0.9 during the screening period.
  7. Agree to adhere to contraception during participation in the project and for 6 months after completion of the trial.
  8. Willing to sign the informed consent form.

Exclusion Criteria:

  1. Subjects who have had any serious acute illness within 8 weeks.
  2. Subjects with a history of active autoimmune disease or autoimmune disease requiring systemic therapy.
  3. Pre-treatment/exposure to any other immune checkpoint inhibitors [e.g., anti-programmed cell death protein 1 (PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.].
  4. The patient has been treated with

    1. Received previous treatment with other anti-submarine drugs within 30 days prior to enrollment.
    2. Received radiotherapy or chemotherapy 30 days prior to screening.
    3. Received immunosuppressive therapy 60 days prior to screening.
    4. Treatment with immunomodulators (e.g., interleukins, interferons), hydroxyurea, or phosphonates 60 days prior to screening.
    5. HIV vaccine or systemic cytotoxic chemotherapy 60 days prior to screening.
    6. Prior immunoglobulin (IgG) therapy.
    7. Previous blood transfusion or cell growth factor therapy 90 days prior to screening.
    8. Use of rifampicin, rifabutin, etc. at the time of screening or during the planned treatment phase.
  5. Laboratory tests meet the following criteria.

    1. absolute neutrophil count (ANC) <1.50×109/L; hemoglobin (Hb) <105 g/L (male) or <95 g/L (female); platelets <75×10^9/μ L; international normalized ratio (INR) >1× upper limit of normal (ULN).
    2. Serum alanine aminotransferase (SGPT/ALT) >1.5× upper limit of normal (ULN), serum aspartate aminotransferase (SGOT/AST) >1.5× upper limit of normal (ULN), total bilirubin, direct bilirubin >1.5× upper limit of normal (ULN), serum creatinine >1.5× upper limit of normal (ULN) × upper limit of normal value (ULN).
    3. Five abnormal thyroid functions with clinical significance: tests include triiodothyronine (T3), tetraiodothyronine (T4), free triiodothyronine (FT3), free tetraiodothyronine (FT3), free tetraiodothyronine (FT4), and thyroid stimulating hormone (TSH).
    4. Abnormal and clinically significant adrenaline tests, which must include at least ACTH and cortisol. Abnormal and clinically significant blood glucose and glycated hemoglobin.
  6. Abnormal and clinically significant twelve-lead ECG at the time of enrollment.
  7. Subjects with interstitial changes on chest CT at the time of enrollment.
  8. Subjects with severe cardiac disease, symptomatic or asymptomatic arrhythmias.
  9. Patients with co-infection with HBV, HCV, syphilis, etc., patients with diabetes mellitus, and patients with other liver diseases.
  10. Subjects with a history of active or suspected malignancy or malignant disease (except basal cell skin cancer or in situ cervical cancer) within five years.
  11. Subjects with a history of tuberculosis or active tuberculosis.
  12. Subjects with psychiatric or substance abuse disorders known to interfere with study requirements.
  13. Subjects who have received immunomodulation or immunosuppression within 24 weeks prior to the first dose of study drug (including any dose of IV/oral [PO] steroids, but excluding steroids by inhalation, topical, or by local injection) within 24 weeks prior to the first dose of the study drug.
  14. Pregnant and lactating women, or men and women who intend to conceive a child during the study period.
  15. Psychiatric patients or those whose substance abuse interferes with the conduct of the trial.
  16. Histone deacetylase inhibitors, such as valproate, butyrate, and phenylbutyrate, but may be enrolled after a 28-day elution period.
  17. Patients with severe cardiac insufficiency [New York Heart Association (NYHA) Cardiac Insufficiency Classification Class IV].
  18. Any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, within 6 months prior to enrollment; normatively treated uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); cardiomyopathy
  19. Patients with significant QT/QTC interval during the screening period (Fridericia formula.

(19) Patients with a significant prolongation of the QT/QTC interval (Fridericia formula: QTcF=QT/RR0.33) during the screening period (e.g., repeated measurements showing a QTc interval >450 ms, or another risk of torsional ventricular tachycardia [TdP] [e.g., heart failure, hypokalemia, familial long QT syndrome]) or combination of drugs that may cause prolongation of the QT/QTc interval.

(20) Known allergy or anti-drug antibodies to drugs or excipients used in this trial.

(21) Those who are judged by the investigator to be unsuitable for participation in this trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05129189


Contacts
Layout table for location contacts
Contact: Jun Chen, M.D +86-21-37990333 ext 3222 qtchenjun@163.com
Contact: Shanghai Public Health Clinical Center Chen, M.D +86-21-37990333 ext 3222 qtchenjun@163.com

Locations
Layout table for location information
China, Shanghai
Shanghai Public Health Clinical Center Recruiting
Shanghai, Shanghai, China, 201508
Contact: Jun Chen, M.D    +86-021-37990333 ext 3222    qtchenjun@163.com   
Sponsors and Collaborators
Shanghai Public Health Clinical Center
Layout table for additonal information
Responsible Party: Jun Chen, MD, Deputy chief physician, Shanghai Public Health Clinical Center
ClinicalTrials.gov Identifier: NCT05129189    
Other Study ID Numbers: ASC22
First Posted: November 22, 2021    Key Record Dates
Last Update Posted: September 19, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Chen, MD, Shanghai Public Health Clinical Center:
Functional cure of HIV, ASC22,PD-1
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Blood-Borne Infections
Communicable Diseases
Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases